Drug Trial Radar · NCT03182504
A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Apr 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Jun 15, 2017
Primary completion
Aug 10, 2017
Study completion Aug 10, 2017
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the intrapulmonary penetration of nacubactam in healthy volunteers. Nacubactam is a novel non-beta-lactam beta-lactamase inhibitor being developed as a combination therapy with the beta-lactam meropenem for the treatment of serious gram-negative bacterial infections. Adult male and female healthy participants will receive a single intravenous infusion of nacubactam co-administered with meropenem and then undergo a bronchoalveolar lavage (BAL) procedure to collect lung epithelial lining fluid (ELF) for measurement of intrapulmonary concentrations of nacubactam and meropenem.
Conditions
- Gram-negative Bacterial Infections
Interventions
nacubactamDrug
Participants will receive a single 2000 milligram (mg) intravenous (IV) infusion of nacubactam over 1.5 hours.
meropenemDrug
Participants will receive a single 2000 mg IV infusion of meropenem over 1.5 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Epithelial Lining Fluid (ELF) Concentration of Nacubactam to Plasma Concentration of Nacubactam RatioTime frame: At 2, 3, 4, 6 and 8 hours after study drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pulmonary Associates Clinical Trials (PACT)
Phoenix, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.